Top

Published in:

01-09-2014 | Gastrointestinal Oncology

Low Creatinine Clearance is a Risk Factor for D2 Gastrectomy after Neoadjuvant Chemotherapy

Authors: Tsutomu Hayashi, MD, Toru Aoyama, MD, Kazuaki Tanabe, MD, Kazuhiro Nishikawa, MD, Yuichi Ito, MD, Takashi Ogata, MD, Haruhiko Cho, MD, Satoshi Morita, PhD, Yumi Miyashita, Akira Tsuburaya, MD, Junichi Sakamoto, MD, Takaki Yoshikawa, MD

Published in: Annals of Surgical Oncology | Issue 9/2014

Abstract

Background

The feasibility and safety of D2 surgery following neoadjuvant chemotherapy (NAC) has not been fully evaluated in patients with gastric cancer. Moreover, risk factor for surgical complications after D2 gastrectomy following NAC is also unknown. The purpose of the present study was to identify risk factors of postoperative complications after D2 surgery following NAC.

Methods

This study was conducted as an exploratory analysis of a prospective, randomized Phase II trial of NAC. The surgical complications were assessed and classified according to the Clavien–Dindo classification. A uni- and multivariate logistic regression analyses were performed to identify risk factors for morbidity.

Results

Among 83 patients who were registered to the Phase II trial, 69 patients received the NAC and D2 gastrectomy. Postoperative complications were identified in 18 patients and the overall morbidity rate was 26.1 %. The results of univariate and multivariate analyses of various factors for overall operative morbidity, creatinine clearance (CCr) ≤ 60 ml/min (P = 0.016) was identified as sole significant independent risk factor for overall morbidity. Occurrence of pancreatic fistula was significantly higher in the patients with a low CCr than in those with a high CCr.

Conclusions

Low CCr was a significant risk factor for surgical complications in D2 gastrectomy after NAC. Careful attention is required for these patients.

Ohtsu A, Yoshida S, Saijo N. Disparities in gastric cancer chemotherapy between the East and West. J Clin Oncol. 2006;24:2188–96.PubMedCrossRef

Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14:101–12.CrossRef

Park JM, Kim YH. Current approaches to gastric cancer in Korea. Gastrointest Cancer Res. 2008;2:137–44.PubMedCentralPubMed

Okines A, Verheij M, Allum W, Cunningham D, Cervantes A; ESMO Guidelines Working Group. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and followup. Ann Oncol. 2010;21(Suppl 5):v50–4.PubMedCrossRef

NCCN. NCCN Clinical Practice Guidelines in Oncology. Gastric Cancer. Version 2.2011. 2011. http://www.nccn.org. Accessed 5 Dec 2011.

Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–20.PubMedCrossRef

Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomized controlled trial. Lancet. 2012;28:315–21.CrossRef

Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 1993;355:11-20.CrossRef

Yoshikawa T, Rino Y, Yukawa N, Oshima T, Tsuburaya A, Masuda M. Neoadjuvant chemotherapy for gastric cancer in japan: a standing position by comparing with adjuvant chemotherapy. Surg Today. 2013;44(1):11–21.PubMedCrossRef

10.

Docetaxel+Oxaliplatin+S-1 (DOS) Regimen as Neoadjuvant Chemotherapy in Advanced Gastric Cancer (PRODIGY). ClinicalTrials.gov Identifier: NCT01515748.

11.

SOX Regimen as Neoadjuvant Chemotherapy for AJCC Stage II-III Gastric Cancer (RESONANCE). ClinicalTrials.gov Identifier: NCT01583361.

12.

Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29:1715–21.PubMedCrossRef

13.

Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol. 2010;28:5210–8.PubMedCentralPubMedCrossRef

14.

Wang ZH, Zhang SZ, Zhang ZY, Zhang CP, Hu HS, Kirwan J, et al. The influence of intraarterial high-dose cisplatin with concomitant irradiation on arterial microanastomosis: an experimental study. Am J Clin Oncol. 2009;32:158–62.PubMedCrossRef

15.

Yoshikawa T, Sasako M, Yamamoto S, Sano T, Imamura H, Fujitani K, et al. Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer. Br J Surg. 2009;96:1015–22.PubMedCrossRef

16.

Iwasaki Y, Sasako M, Yamamoto S, Nakamura K, Sano T, Katai H, et al. Phase II study of preoperative chemotherapy with S-1 and cisplatin followed by gastrectomy for clinically resectable type 4 and large type 3 gastric cancers (JCOG0210). J Surg Oncol. 2013;107:741–5.PubMedCrossRef

17.

Kinoshita T, Sasako M, Sano T, Katai H, Furukawa H, Tsuburaya A, et al. Phase II trial of S-1 for neoadjuvant chemotherapy against scirrhous gastric cancer (JCOG 0002). Gastric Cancer. 2009;12:37–42.PubMedCrossRef

18.

Tsuburaya A, Nagata N, Cho H, Hirabayashi N, Kobayashi M, Kojima H, et al. Phase II trial of paclitaxel and cisplatin as neoadjuvant chemotherapy for locally advanced gastric cancer. Cancer Chemother Pharmacol. 2013;71:1309–14.PubMedCrossRef

19.

Fujitani K, Ajani JA, Crane CH, Feig BW, Pisters PW, Janjan N, et al. Impact of induction chemotherapy and preoperative chemoradiotherapy on operative morbidity and mortality in patients with locoregional adenocarcinoma of the stomach or gastroesophageal junction. Ann Surg Oncol. 2007;14:2010–7.PubMedCrossRef

20.

Yoshikawa T, Tsuburaya A, Morita S, Kodera Y, Ito S, Cho H, et al. A comparison of multimodality treatment: two or four courses of paclitaxel plus cisplatin or S-1 plus cisplatin followed by surgery for locally advanced gastric cancer, a randomized Phase II trial (COMPASS). Jpn J Clin Oncol. 2010;40:369–72.PubMedCrossRef

21.

Yoshikawa T, Tanabe K, Nishikawa K, Ito Y, Matsui T, Kimura Y, et al. Induction of a pathological complete response by four courses of neoadjuvant chemotherapy for gastric cancer: early results of the randomized phase II COMPASS Trial. Ann Surg Oncol. 2014;21:213–9.PubMedCrossRef

22.

Habermann CR, Weiss F, Riecken R, Honarpisheh H, Bohnacker S, Staedtler S, et al. Preoperative staging of gastric adenocarcinoma: comparison of helical CT and endoscopic US. Radiology 2004;230:465–70.PubMedCrossRef

23.

Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors (RECIST guidelines) J Natl Cancer Inst. 2000;92:205–16.PubMedCrossRef

24.

Clavien PA, Barkun J, de Oliveira ML, Vauthey JN, Dindo D, Schulick RD, et al. The Clavien-Dindo classification of surgical complications: five-year experience. Ann Surg 2009;250:187–96.PubMedCrossRef

25.

Vaziri ND, Pahl MV, Crum A, Norris K. Effect of uremia on structure and function of immune system. J Ren Nutr. 2012;22:149–56.PubMedCentralPubMedCrossRef

26.

Sasako M. Risk factors for surgical treatment in the Dutch Gastric Cancer Trial. Br J Surg. 1997;84:1567–71.PubMedCrossRef

27.

Kodera Y, Sasako M, Yamamoto S, Sano T, Nashimoto A, Kurita A, et al. Identification of risk factors for the development of complications following extended and superextended lymphadenectomies for gastric cancer. Br J Surg. 2005;92:1103–9.PubMedCrossRef

28.

Urien S, Lokiec F. Population pharmacokinetics of total and unbound plasma cisplatin in adult patients. Br J Clin Pharmacol. 2004;57:756–63.PubMedCentralPubMedCrossRef

29.

Kohn R. Human aging and disease. J Chronic Dis 1963;16:5–21.PubMedCrossRef

30.

Bonenkamp JJ, Songun I, Hermans J, eSasako M, Welvaart K, Plukker JT, et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet. 1995;345:745–8.PubMedCrossRef

31.

Tsujinaka T, Sasako M, Yamamoto S, Sano T, Kurokawa Y, Nashimoto A, Kurita A, Katai H, Shimizu T, Furukawa H, Inoue S, Hiratsuka M, Kinoshita T, Arai K, Yamamura Y; Gastric Cancer Surgery Study Group of Japan Clinical Oncology Group. Influence of overweight on surgical complications for gastric cancer: results from a randomized control trial comparing D2 and extended para-aortic D3 lymphadenectomy (JCOG9501). Ann Surg Oncol. 2007;14(2):355–61.PubMedCrossRef

Title: Low Creatinine Clearance is a Risk Factor for D2 Gastrectomy after Neoadjuvant Chemotherapy
Authors: Tsutomu Hayashi, MD
Toru Aoyama, MD
Kazuaki Tanabe, MD
Kazuhiro Nishikawa, MD
Yuichi Ito, MD
Takashi Ogata, MD
Haruhiko Cho, MD
Satoshi Morita, PhD
Yumi Miyashita
Akira Tsuburaya, MD
Junichi Sakamoto, MD
Takaki Yoshikawa, MD
Publication date: 01-09-2014
Publisher: Springer US
Published in: Annals of Surgical Oncology / Issue 9/2014
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-014-3670-1

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Low Creatinine Clearance is a Risk Factor for D2 Gastrectomy after Neoadjuvant Chemotherapy

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 9/2014

Letter to the Editor of Annals of Surgical Oncology Concerning “Robotic versus Open Pancreatectomy: A Systematic Review and Meta-analysis”

Innovative Rapid Gene Methylation Analysis of Surgical Margin Tissues in Head and Neck Cancer

18F-Fluorodeoxyglucose Positron Emission Tomography versus Computed Tomography in Predicting Histopathological Response to Epidermal Growth Factor Receptor–Tyrosine Kinase Inhibitor Treatment in Resectable Non-Small Cell Lung Cancer

Axillary Ultrasonography in Breast Cancer Patients Helps in Identifying Patients Preoperatively with Limited Disease of the Axilla

More Harm than Good?

Reply to ‘Letter to the Editor of Annals of Surgical Oncology Concerning “Robotic versus Open Pancreatectomy: A Systematic Review and Meta-Analysis”,’ by Petrucciani Niccolò, et al. (ASO-2013-09-1427)